PRVL insider filings
Prevail Therapeutics Inc. — 18 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2021-01-26. Screen PRVL transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for PRVL between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Prevail Therapeutics Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2021-01-26 | 4 | Abeliovich Asa — President & CEO, Director | Code (U): 2,385,756 · Disposition to issuer (D): 1,329,219 (derivative) @ $0 · Disposition to issuer (D): 178,681 (derivative) @ $0 · Disposition to issuer (D): 250,000 (derivative) @ $0 | EDGAR |
| 2021-01-26 | 4 | Carson William H. — Director | Disposition to issuer (D): 34,000 (derivative) @ $0 | EDGAR |
| 2021-01-26 | 4 | Dai Yong — Chief Technology Officer | Disposition to issuer (D): 200,172 (derivative) @ $0 · Disposition to issuer (D): 126,567 (derivative) @ $0 · Disposition to issuer (D): 43,500 (derivative) @ $0 | EDGAR |
| 2021-01-26 | 4 | Hefti Franz — Chief Development Officer | Disposition to issuer (D): 266,895 (derivative) @ $0 · Disposition to issuer (D): 59,844 (derivative) @ $0 · Disposition to issuer (D): 62,200 (derivative) @ $0 | EDGAR |
| 2021-01-26 | 4 | Kaplan Brett — Chief Financial Officer | Disposition to issuer (D): 347,004 (derivative) @ $0 · Disposition to issuer (D): 64,565 (derivative) @ $0 · Disposition to issuer (D): 95,000 (derivative) @ $0 | EDGAR |
| 2021-01-26 | 4 | Minkow Emily — Chief Business Officer | Code (U): 13,000 · Disposition to issuer (D): 149,000 (derivative) @ $0 · Disposition to issuer (D): 104,895 (derivative) @ $0 · Disposition to issuer (D): 108,854 (derivative) @ $0 · Disposition to issuer (D): 54,000 (derivative) @ $0 | EDGAR |
| 2021-01-26 | 4 | Schwartz Kira M. — General Counsel | Disposition to issuer (D): 100,000 (derivative) @ $0 | EDGAR |
| 2021-01-26 | 4 | Sevigny Jeffrey — Chief Medical Officer | Disposition to issuer (D): 400,342 (derivative) @ $0 · Disposition to issuer (D): 122,439 (derivative) @ $0 · Disposition to issuer (D): 89,000 (derivative) @ $0 | EDGAR |
| 2021-01-26 | 4 | Sheng Morgan — Director | Disposition to issuer (D): 20,000 (derivative) @ $0 · Disposition to issuer (D): 17,000 (derivative) @ $0 | EDGAR |
| 2021-01-26 | 4 | Nussbaum Ran — Director | Code (U): 1,576,881 · Disposition to issuer (D): 17,000 (derivative) @ $0 | EDGAR |
| 2021-01-26 | 4 | Nader Francois — Director | Code (U): 23,747 · Disposition to issuer (D): 133,447 (derivative) @ $0 · Disposition to issuer (D): 32,000 (derivative) @ $0 · Disposition to issuer (D): 17,000 (derivative) @ $0 | EDGAR |
| 2021-01-26 | 4 | Thompson Peter A. — Director, 10% owner | Code (U): 13,822,463 · Disposition to issuer (D): 17,000 (derivative) @ $0 | EDGAR |
| 2021-01-26 | 4 | Adams Timothy M — Director | Disposition to issuer (D): 32,400 (derivative) @ $0 · Disposition to issuer (D): 17,000 (derivative) @ $0 | EDGAR |
| 2021-01-26 | 4 | GORDON CARL L — Director, 10% owner | Code (U): 13,822,463 · Disposition to issuer (D): 17,000 (derivative) @ $0 | EDGAR |
| 2021-01-26 | 4 | ORBIMED ADVISORS LLC — Director, 10% owner OrbiMed Capital GP VI LLC — Director, 10% owner | Code (U): 13,822,463 | EDGAR |
| 2021-01-22 | 4 | Tyto Acquisition Corp — 10% owner ELI LILLY & Co — 10% owner | Purchase (P): 34,284,789 @ $22.50 | EDGAR |
| 2020-12-31 | 4 | Abeliovich Asa — President & CEO, Director | Option exercise (M): 5,256 @ $0.18 · Option exercise (M): 120,537 @ $10.26 · Tax withholding (F): 89,037 @ $23.02 · Option exercise (M): 5,256 (derivative) @ $0 · Option exercise (M): 120,537 (derivative) @ $0 | EDGAR |
| 2020-09-11 | 4 | Carson William H. — Director | Grant/award (A): 34,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Prevail Therapeutics Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2021-01-22 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2020-12-15 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2020-11-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2020-11-12 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2020-11-02 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2020-09-10 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2020-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=PRVL returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs